Hep B Vaccine Delay Sparks Health Crisis Fears

In late 2025, the Advisory Committee on Immunization Practices altered its long-standing universal hepatitis B birth-dose vaccine recommendation. The new guidance suggests "shared clinical decision-making" for infants born to hepatitis B-negative mothers and delaying the first vaccine dose until at least two months of age.

Recent studies published in JAMA Pediatrics indicate severe potential consequences. One model projects that a two-month delay for a single U.S. birth cohort of 3.6 million infants could result in 90 additional acute hepatitis B infections, 76 chronic infections, 29 hepatitis B-related deaths, and $16.4 million in healthcare costs. These figures are considered conservative best-case scenarios.

Historical precedent from 1999, when a similar delay was implemented, saw a drastic drop in birth-dose coverage for infants of unscreened mothers, from 53 percent to 7 percent. Applying that historical data to the current policy change suggests an increase of 628 infant infections per cohort, with approximately 90 percent of perinatally acquired hepatitis B becoming chronic and potentially leading to premature death.

The article warns of a cascading effect, as the hepatitis B vaccine is often administered alongside other universal newborn interventions like vitamin K and erythromycin ointment. Changes to one may cast suspicion on the others, leading to refusals of all. Clusters of vitamin K deficiency bleeding and blindness from ophthalmia neonatorum have already been linked to vaccine skepticism in the U.S. and Australia.

The Advisory Committee on Immunization Practices, whose recommendations influence federal vaccine financing and insurance coverage, has recently undergone significant changes. In June 2025, the entire committee was replaced by new appointees, some with documented histories of vaccine skepticism. This shift is seen as a primary driver for the recent policy changes. Congressional oversight committees are urged to investigate the committee's composition, screening processes, and the evidence behind the December vote. Legislation to protect committee members from arbitrary dismissal is also proposed to restore the CDC and ACIP's role as a public health firewall.

As of May 12, 2026, the consequences of these policy shifts are beginning to emerge, with the potential for severe health impacts on newborns. The virus and the risk of bleeding, unlike policy changes, do not wait.